A retrospective study of conversion from tacrolimus-based to sirolimus-based immunosuppression in orthotopic liver transplant recipients

Experimental and Clinical Transplantation

Volumn 6, Issue 2, 2008, Pages 113-117

  Yu, Si ^a   He, Xiaoshun ^a   Yang, Lu ^a   Ma, Yi ^a   Zhu, Xiaofeng ^a   Ju, Weiqiang ^a   Huang, Jiefu ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

Conversion; Immunosuppression; Orthotopic liver transplant; Sirolimus

Indexed keywords

ANTILIPEMIC AGENT; CYCLOSPORIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RAPAMYCIN; TACROLIMUS;

ACUTE GRAFT REJECTION; ADULT; AGED; ARTICLE; CHINA; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG PULSE THERAPY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GRAFT RECIPIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LOADING DRUG DOSE; MALE; MORNING DOSAGE; MOUTH ULCER; RETROSPECTIVE STUDY; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL; UNIVERSITY HOSPITAL;

ADULT; AGED; CYCLOSPORINE; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SIROLIMUS; TACROLIMUS; TREATMENT OUTCOME;

EID: 53649096384     PISSN: 13040855     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Chang GJ, Mahanty HD, Quan D, et al. Experience with the use of sirolimus in liver transplantation--use in patients for whom calcineurin inhibitors are contraindicated. Liver Transpl. 2000;6(6):734-740.
2. Gonwa TA, Hricik DE, Brinker K, Grinyo JM, Schena FP; Sirolimus Renal Function Study Group. Improved renal function in sirolimustreated renal transplant patients after early cyclosporine elimination. Transplantation. 2002;74(11):1560-1567.
3. Diekmann F, Waiser J, Fritsche L, Dragun D, Neumayer HH, Budde K. Conversion to rapamycin in renal allograft recipients with biopsy-proven calcineurin inhibitor-induced nephrotoxicity. Transplant Proc. 2001;33(7-8):3234-3235.
4. Flechner SM, Goldfarb D, Modlin C, et al. Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine. Transplantation. 2002;74(8):1070-1076.
5. Snell GI, Levvey BJ, Chin W, et al. Sirolimus allows renal recovery in lung and heart transplant recipients with chronic renal impairment. J Heart Lung Transplant. 2002;21(5):540-546.
6. Nair S, Eason J, Loss G. Sirolimus monotherapy in nephrotoxicity due to calcineurin inhibitors in liver transplant recipients. Liver Transpl. 2003;9(2):126-129.
7. Fairbanks KD, Eustace JA, Fine D, Thuluvath PJ. Renal function improves in liver transplant recipients when switched from a calcineurin inhibitor to sirolimus. Liver Transpl. 2003;9(10):1079-1085.
8. Terminology for hepatic allograft rejection. International Working Party. Hepatology. 1995;22(2):648-654.
9. Ogino S, Hashikura Y, Katsuyama Y, et al. Conversion from tacrolimus to cyclosporine microemulsion therapy in liver transplant recipients. Transplant Proc. 2004;36(suppl 2):299S-301S.
10. Akamatsu N, Sugawara Y, Tamura S, et al. Late-onset acute rejection after living donor liver transplantation. World J Gastroenterol. 2006;12(41):6674-6677.
11. Pawarode A, Fine DM, Thuluvath PJ. Independent risk factors and natural history of renal dysfunction in liver transplant recipients. Liver Transpl. 2003;9(7):741-747.
12. Morris RE. Rapamycin: FK506's fraternal twin or distant cousin? Immunol Today. 1991;12(5):137-140.
13. Sehgal SN. Rapamune (Sirolimus, rapamycin): an overview and mechanism of action. Ther Drug Monit. 1995;17(6):660-665.
14. Liu J, Farmer JD Jr, Lane WS, Friedman J, Weissman I, Schreiber SL. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell. 1991;66(4):807-815.
15. Pridöhl O, Heinemann K, Hartwig T, et al. Low-dose immunosuppression with FK 506 and sirolimus after liver transplantation: 1-year results. Transplant Proc. 2001;33(7-8):3229-3231.
16. Trotter JF, Wachs M, Bak T, et al. Liver transplantation using sirolimus and minimal corticosteroids (3-day taper). Liver Transpl. 2001;7(4):343-351.
17. Forgacs B, Merhav HJ, Lappin J, Mieles L. Successful conversion to rapamycin for calcineurin inhibitor-related neurotoxicity following liver transplantation. Transplant Proc. 2005;37(4):1912-1914.
18. Kniepeiss D, Iberer F, Schaffellner S, Jakoby E, Duller D, Tscheliessnigg KH. Nonnephrotoxic immunosuppression in patients after liver transplantation. Int Immunopharmacol. 2005;5(1):133-136.
19. Groth CG, Backman L, Morales JM, et al. Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. Transplantation. 1999;67(7):1036-1042.
20. Hidalgo M, Rowinsky EK. The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Oncogene. 2000;19(56):6680-6686.
21. Schumacher G, Oidtmann M, Rosewicz S, et al. Sirolimus inhibits growth of human hepatoma cells in contrast to tacrolimus which promotes cell growth. Transplant Proc. 2002;34(5):1392-1393.